evaluated the actions of a specific RIG-I agonist RNA against two distinct human hepatocellular carcinoma cell lines. RAR is ...

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Hepatocellular carcinoma (HCC), the third leading cause ... Although its overexpression or knockdown did not impact tumor cell proliferation, it markedly promoted subcutaneous tumor growth in ...

Given the success of Research Topic <a href=" in Chemotherapy-Resistant Hepatocellular Carcinoma and the rapidly evolving ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Findings from the CheckMate 9DW trial support the FDA approval of nivolumab and ipilimumab in unresectable hepatocellular carcinoma ...

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell ...